WO2019080193A1 - 一种包封游离虾青素的脂质体及其制备方法 - Google Patents
一种包封游离虾青素的脂质体及其制备方法Info
- Publication number
- WO2019080193A1 WO2019080193A1 PCT/CN2017/110628 CN2017110628W WO2019080193A1 WO 2019080193 A1 WO2019080193 A1 WO 2019080193A1 CN 2017110628 W CN2017110628 W CN 2017110628W WO 2019080193 A1 WO2019080193 A1 WO 2019080193A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- free astaxanthin
- liposome
- astaxanthin
- cholesterol
- egg yolk
- Prior art date
Links
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 title claims abstract description 48
- 235000013793 astaxanthin Nutrition 0.000 title claims abstract description 48
- 239000001168 astaxanthin Substances 0.000 title claims abstract description 48
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 title claims abstract description 48
- 229940022405 astaxanthin Drugs 0.000 title claims abstract description 48
- 239000002502 liposome Substances 0.000 title claims abstract description 41
- 238000002360 preparation method Methods 0.000 title abstract description 12
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 36
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 17
- 150000002632 lipids Chemical class 0.000 claims abstract description 15
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000000872 buffer Substances 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 8
- 239000007788 liquid Substances 0.000 claims abstract description 6
- 238000001704 evaporation Methods 0.000 claims abstract description 3
- 239000007787 solid Substances 0.000 claims abstract description 3
- 238000009210 therapy by ultrasound Methods 0.000 claims abstract 2
- 239000000243 solution Substances 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 6
- 239000012475 sodium chloride buffer Substances 0.000 claims description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 4
- 102000002322 Egg Proteins Human genes 0.000 claims description 2
- 108010000912 Egg Proteins Proteins 0.000 claims description 2
- 238000004821 distillation Methods 0.000 claims description 2
- 239000012153 distilled water Substances 0.000 claims description 2
- 235000013345 egg yolk Nutrition 0.000 claims description 2
- 210000002969 egg yolk Anatomy 0.000 claims description 2
- 230000008020 evaporation Effects 0.000 claims description 2
- 210000000232 gallbladder Anatomy 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 238000003260 vortexing Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 5
- 239000002245 particle Substances 0.000 abstract description 2
- 238000005538 encapsulation Methods 0.000 abstract 1
- 239000000523 sample Substances 0.000 abstract 1
- 239000008346 aqueous phase Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 241000238557 Decapoda Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000000823 artificial membrane Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000002047 solid lipid nanoparticle Substances 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003505 terpenes Chemical group 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
- A23L5/30—Physical treatment, e.g. electrical or magnetic means, wave energy or irradiation
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
- A23L5/30—Physical treatment, e.g. electrical or magnetic means, wave energy or irradiation
- A23L5/32—Physical treatment, e.g. electrical or magnetic means, wave energy or irradiation using phonon wave energy, e.g. sound or ultrasonic waves
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
Definitions
- the invention relates to a liposome preparation, in particular to a liposome preparation containing free astaxanthin, belonging to the technical field of health foods.
- Liposomes are an artificial membrane.
- the hydrophilic head of the phospholipid molecule in water is inserted into the water, and the hydrophobic tail of the liposome extends to the air, and a spherical liposome which forms a double-layered lipid molecule after agitation, ranging from 25 to 1000 nm in diameter.
- Liposomes can be used for transgenic, or prepared drugs, using the characteristics of liposome fusion with cell membranes to deliver drugs into the interior of cells.
- Biological definition When amphiphilic molecules such as phospholipids and sphingolipids are dispersed in the aqueous phase, the hydrophobic tails of the molecules tend to aggregate together, avoiding the aqueous phase, while the hydrophilic head is exposed to the aqueous phase, forming a bilayer structure. Closed vesicles, called liposomes. Pharmacy Definition: Liposomes: Microcapsules formed by encapsulating a drug in a lipid-like bilayer.
- Astaxanthin is a purple crystal with a molecular formula of C40H5204 and a relative molecular weight of 596.86. It is a terpene-based unsaturated compound belonging to the lutein- ⁇ -carotene family. Natural astaxanthin has strong antioxidant capacity, can effectively remove oxygen free radicals in cells, and prevent oxidative damage of tissues, cells and DNA. It is called "super vitamin E”. At the same time, astaxanthin also has physiological activities such as anti-aging, anti-tumor and prevention of cardiovascular and cerebrovascular diseases, and has important application value in industries such as food, health care products, medicines and cosmetics.
- Astaxanthin is a fat-soluble ingredient with low solubility in water, resulting in low absorption and bioavailability in the gastrointestinal tract.
- the structure due to the high degree of unsaturation of astaxanthin molecules, the structure contains more unsaturated bonds, which are prone to heterogeneity and degradation under conditions of light, acid, alkali and oxygen, resulting in poor stability.
- the existing technical defects of astaxanthin in water with low solubility and poor stability have become a technical bottleneck in the application of the medical field, and further improvement is needed.
- the main object of the present invention is to provide a free astaxanthin liposome and a preparation method thereof for solving the shrimp The problem of low solubility and poor stability of chlorophyll in water.
- the invention provides a free astaxanthin liposome, which is composed of the following components: egg yolk lecithin, cholesterol, free astaxanthin, a buffer solution, wherein the mass ratio of egg yolk lecithin to cholesterol is 6-10:1, The mass ratio of egg yolk lecithin to free astaxanthin is 120-200:1, and the solid-liquid ratio of free astaxanthin to buffer is (mg/ml) 1:6-10.
- the cholesterol is any one of protein cholesterol, serum cholesterol, egg yolk cholesterol or gallbladder cholesterol.
- the buffer is a 0.05-0.15% sodium chloride buffer solution.
- the buffer is prepared by mixing 0.5-1.5 mg of solid sodium chloride with 100 ml of single distilled water.
- a preparation process of a liposome encapsulating free astaxanthin adopts the following steps:
- organic solvent described in the step 2) is dichloromethane.
- step 3 the water bath ultrasonic system is ultrasonicated for 5-15 minutes under the condition of power 60-80 Hz.
- step 3 the vacuum degree of evaporation under vacuum is 0.06-0.1 Mpa, and the distillation time is 0.5 h.
- the ultrasonic time described in the step 6) is 3-5 minutes, the ultrasonic frequency is 40-60%, and the ultrasonic power is 200-250W.
- astaxanthin is a photosensitive substance, and all the above operations need to be operated in the dark, and the prepared free astaxanthin liposome also needs to be stored in the dark.
- the beneficial effects of the invention are: the free astaxanthin liposome is a lipid core inside, and the outside is an aqueous phase, which increases the solubility of astaxanthin in water, thereby improving the fat-soluble component shrimp green Absorption rate and bioavailability in the gastrointestinal tract; at the same time, astaxanthin solid lipid nanoparticles are translucent, emulsion The average particle size, zeta potential, dispersion index PDI and other indicators are good, and it is not easy to beomerized and degraded, and has good stability; the free astaxanthin liposome of the present invention opens up the application range of liposome, and uses liposome As a carrier, the free astaxanthin is embedded, the preparation process is simple, the equipment requirements are low, and the utility model is convenient for popularization and application.
- the ultrasonic time was 4 minutes, the ultrasonic frequency was 50%, and the ultrasonic power was 225 W.
- the ultrasonic power was 225 W.
- the invention discloses a liposome encapsulating free astaxanthin and a preparation method thereof, and the liposome is used as a carrier to embed free astaxanthin, wherein the preparation process is simple, the equipment requirement is low, the utility model is convenient for popularization and application, and the large-scale batch is easy to realize. produce.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Manufacturing Of Micro-Capsules (AREA)
Abstract
本发明提供一种虾青素脂质体制剂及其制备方法,该虾青素脂质体由蛋黄卵磷脂、胆固醇、游离虾青素、与缓冲液制成,其中,蛋黄卵磷脂与胆固醇的质量比为6-10:1,蛋黄卵磷脂与游离虾青素的质量比为120-200:1,游离虾青素与缓冲液的固液比为(mg/ml)为1:6-10。本发明还公开了一种包封游离虾青素的脂质体的制备方法。本发明的包封游离虾青素的脂质体及制备方法,通过采用逆向蒸发法制备游离虾青素脂质体,并采用超声波探头仪进行超声处理,直至为稳定的体系。该方法可显著提高游离虾青素脂质体的稳定性,通过调整脂质成分和缓冲液的比例,以及优化超声工艺等步骤,可以有效的控制脂质体的粒径,提高载药量和包封率。
Description
本发明涉及一种脂质体制剂,尤其是一种含有游离虾青素的脂质体制剂,属于保健食品技术领域。
脂质体是一种人工膜。在水中磷脂分子亲水头部插入水中,脂质体疏水尾部伸向空气,搅动后形成双层脂分子的球形脂质体,直径25-1000nm不等。脂质体可用于转基因,或制备的药物,利用脂质体可以和细胞膜融合的特点,将药物送入细胞内部。生物学定义:当两性分子如磷脂和鞘脂分散于水相时,分子的疏水尾部倾向于聚集在一起,避开水相,而亲水头部暴露在水相,形成具有双分子层结构的的封闭囊泡,称为脂质体。药剂学定义:脂质体:系指将药物包封于类脂质双分子层内而形成的微型泡囊体。
虾青素(Astaxanthin)为紫色晶体,分子式为C40H5204,相对分子量为596.86,是一种萜烯类不饱和化合物,类属于叶黄素类-β-胡萝卜素家族。天然虾青素具有极强的抗氧化能力,可以有效的清除细胞内的氧自由基,防止组织、细胞、DNA被氧化损伤,被称为“超级维生素E”。同时,虾青素还具有抗衰老、抗肿瘤和预防心脑血管疾病等生理活性,在食品、保健品、药品和化妆品等行业具有重要的应用价值。
虾青素是一种脂溶性成分,在水中的溶解度低,致使其在胃肠道中的吸收率和生物利用度不高。另外,由于虾青素分子具有高度不饱和性,结构中含有较多的不饱和键,在光、酸碱、氧等条件下易发生异构和降解,导致其稳定性较差。现有的虾青素在水中溶解度低以及稳定性差的技术缺陷已成为其在医药领域里应用的技术瓶颈,有待进一步改进。
针对以上虾青素在实际应用当中出现的问题,有必要对游离虾青素进行包埋并制备游离虾青素脂质体,提高它的生物利用度,延长游离虾青素的寿命,有效地保持其活性,可广泛用于食品、保健品和药品中。
发明内容
本发明的主要目的在于提供一种游离虾青素脂质体及其制备方法,以解决虾
青素在水中溶解度低及稳定性差的问题。
本发明提供了一种游离虾青素脂质体,由以下成份组成:蛋黄卵磷脂、胆固醇、游离虾青素、缓冲液,其中,蛋黄卵磷脂与胆固醇的质量比为6-10:1,蛋黄卵磷脂与游离虾青素的质量比为120-200:1,游离虾青素与缓冲液的固液比为(mg/ml)为1:6-10。
进一步,所述胆固醇为蛋白胆固醇、血清胆固醇、蛋黄胆固醇或胆囊胆固醇中的任一种。
进一步,所述缓冲液为0.05-0.15%的氯化钠缓冲溶液。
进一步,所述缓冲液为0.5-1.5mg固体氯化钠与100ml单蒸水混合制得。
一种包封游离虾青素的脂质体的制备工艺,采用如下步骤:
1)将蛋黄卵磷脂与胆固醇按质量比6-10:1的比例称量,另将蛋黄卵磷脂与游离虾青素的按质量比为120-200:1的比例称量;
2)将以上称量好的物质溶解在有机溶剂中,其中,固液比(mg/mL)为1:15-25,得溶液A;
3)经水浴超声仪超声处理,使混合液变成澄清的单相,再将混合液置于旋转蒸发仪中减压蒸馏直至形成一层脂质薄膜。
4)向脂质薄膜中加入氯化钠缓冲溶液,溶解脂质薄膜,得溶液B;
5)将溶液B涡旋振荡,直至脂质薄膜完全水解。
6)B液溶解完全后超声处理,放4℃冰箱中保存,即得包封游离虾青素的脂质体。
进一步,步骤2)中所述的有机溶剂为二氯甲烷。
进一步,步骤3)中水浴超声仪在功率60-80Hz的条件下,超声5-15分钟。
进一步,步骤3)中减压蒸发真空度为0.06-0.1Mpa,蒸馏时间为0.5h。
进一步,步骤6)中所述的超声时间为3-5分钟,超声频率为40-60%,超声功率为200-250W。
进一步,虾青素为光敏物质,以上一切操作需在避光下操作,制备好的游离虾青素脂质体也需避光存放。
与现有技术相比,本发明的有益效果是:游离虾青素脂质体内部为脂质核,外部为水相,增加了虾青素在水中的溶解度,从而提高了脂溶性成分虾青素在胃肠道中的吸收率和生物利用度;同时,虾青素固体脂质纳米粒呈半透明状,乳液
平均粒径、Zeta电位、分散指数PDI等指标良好,不易发生异构和降解,具有较好的稳定性;本发明游离虾青素脂质体开拓了脂质体的应用范围,运用脂质体作为载体包埋游离虾青素,其制备工艺简单,设备要求较低,便于推广应用。
实施例
将80mg蛋黄卵磷脂、20mg胆固醇和0.5mg游离虾青素溶于2ml二氯甲烷中,得A液。然后在水浴超声仪频率为70Hz的条件下超声10min,使混合液变成澄清的单相。在38℃的水浴,0.09Mpa的真空压下,将混合溶液旋转蒸发0.5h直至形成一层脂质薄膜。向脂质薄膜中加入4ml氯化钠缓冲溶液,溶解脂质薄膜,得溶液B;将溶液B涡旋振荡,直至脂质薄膜完全水解。将B液溶解完全后超声处理,超声时间为4分钟,超声频率为50%,超声功率为225W。放4℃冰箱避光保存,即得包封游离虾青素的脂质体。
上述实施例仅用来进一步说明本发明的一种包封游离虾青素的脂质体及其制备方法,但本发明并不局限于实施例,凡是依据本发明的技术实质对以上实施例所作的任何简单修改、等同变化与修饰,均落入本发明技术方案的保护范围内。
本发明一种包封游离虾青素的脂质体及其制备方法,运用脂质体作为载体包埋游离虾青素,其制备工艺简单,设备要求较低,便于推广应用,易于实现大批量生产。
Claims (9)
- 一种包封游离虾青素的脂质体,其特征在于:包括以下成份:蛋黄卵磷脂、胆固醇、游离虾青素、缓冲液,其中,蛋黄卵磷脂与胆固醇的质量比为6-10:1,蛋黄卵磷脂与游离虾青素的质量比为120-200:1,游离虾青素与缓冲液的固液比为mg/ml为1:6-10。
- 如权利要求1所述的包封游离虾青素的脂质体,其特征在于:所述胆固醇为蛋白胆固醇、血清胆固醇、蛋黄胆固醇或胆囊胆固醇中的任一种。
- 如权利要求1所述的包封游离虾青素的脂质体,其特征在于:所述缓冲液为0.05-0.15%的氯化钠缓冲溶液。
- 如权利要求3所述的包封游离虾青素的脂质体,其特征在于:所述缓冲液为0.5-0.15mg固体氯化钠与100ml单蒸水混合制得。
- 一种包封游离虾青素的脂质体的制备方法,其特征在于:采用如下步骤:1)将蛋黄卵磷脂与胆固醇按质量比6-10:1的比例称量,另将蛋黄卵磷脂与游离虾青素的按质量比为120-200:1的比例称量;2)将以上称量好的物质溶解在有机溶剂中,其中,固液比mg/mL为1:15-25,得溶液A;3)经水浴超声仪超声处理,使混合液变成澄清的单相,再将混合液置于旋转蒸发仪中减压蒸馏直至形成一层脂质薄膜;4)向脂质薄膜中加入氯化钠缓冲溶液,溶解脂质薄膜,得溶液B;5)将溶液B涡旋振荡,直至脂质薄膜完全水解;6)B液溶解完全后超声处理,放4℃冰箱中保存,即得包封游离虾青素的脂质体。
- 如权利要求5所述的包封游离虾青素的脂质体的制备方法,其特征在于:步骤2)中所述的有机溶剂为二氯甲烷。
- 如权利要求5所述的包封游离虾青素的脂质体的制备方法,其特征在于:步骤3)中水浴超声仪在功率60-80Hz的条件下,超声5-15分钟。
- 如权利要求5所述的包封游离虾青素的脂质体的制备方法,其特征在于:步骤3)中减压蒸发真空度为0.06-0.1Mpa,蒸馏时间为0.5h。
- 如权利要求5所述的包封游离虾青素的脂质体的制备方法,其特征在于:步骤6)中所述的超声时间为3-5分钟,超声频率为40-60%,超声功率为200-250W。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711000153.6 | 2017-10-24 | ||
CN201711000153.6A CN109691672A (zh) | 2017-10-24 | 2017-10-24 | 一种包封游离虾青素的脂质体及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019080193A1 true WO2019080193A1 (zh) | 2019-05-02 |
Family
ID=66227760
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2017/110628 WO2019080193A1 (zh) | 2017-10-24 | 2017-11-13 | 一种包封游离虾青素的脂质体及其制备方法 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN109691672A (zh) |
WO (1) | WO2019080193A1 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110558435A (zh) * | 2019-09-30 | 2019-12-13 | 广东海洋大学 | 一种虾青素纳米脂质体及其制备方法和应用 |
CN112791001B (zh) * | 2020-12-18 | 2023-09-29 | 南京理工大学 | 一种虾青素脂质体的制备方法 |
CN112999209A (zh) * | 2021-03-19 | 2021-06-22 | 中国海洋大学 | 海参甾醇脂质体在提高人体顺式虾青素含量制品中的应用 |
CN114652677B (zh) * | 2021-12-27 | 2023-05-05 | 海南全星制药有限公司 | 一种盐酸氨溴索注射液及其制备方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002064110A2 (en) * | 2001-02-13 | 2002-08-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Carotenoid-loaded liposomes |
KR20140054698A (ko) * | 2012-10-29 | 2014-05-09 | 아주대학교산학협력단 | 리포좀 캡슐화를 이용한 산화안정성이 우수한 아스타잔틴의 제조방법 |
CN104997647A (zh) * | 2015-07-09 | 2015-10-28 | 西安艾尔菲生物科技有限公司 | 一种含有虾青素的防晒喷雾剂及其制备方法 |
CN105769820A (zh) * | 2016-04-08 | 2016-07-20 | 华南理工大学 | 一种超临界溶析技术制备虾青素缓释微球制剂的方法 |
CN106726639A (zh) * | 2016-11-28 | 2017-05-31 | 广东工业大学 | 一种peg修饰原花青素脂质体的制备方法 |
CN107271378A (zh) * | 2017-04-13 | 2017-10-20 | 云南民族大学 | 虾青素脂质抗氧化活性的测定方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1443529A (zh) * | 2003-04-15 | 2003-09-24 | 华南理工大学 | 包封果酸的脂质体及其制备方法和应用 |
CN103610642B (zh) * | 2013-12-10 | 2016-05-04 | 中国计量学院 | 一种包封表没食子儿茶素没食子酸酯的脂质体及制备方法 |
CN104824787A (zh) * | 2015-04-07 | 2015-08-12 | 中国计量学院 | 一种包封溶菌酶的脂质体及制备方法 |
CN104983591B (zh) * | 2015-07-09 | 2018-08-28 | 西安艾尔菲生物科技有限公司 | 一种双重修饰β-胡萝卜素脂质体及其制备方法 |
-
2017
- 2017-10-24 CN CN201711000153.6A patent/CN109691672A/zh active Pending
- 2017-11-13 WO PCT/CN2017/110628 patent/WO2019080193A1/zh active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002064110A2 (en) * | 2001-02-13 | 2002-08-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Carotenoid-loaded liposomes |
KR20140054698A (ko) * | 2012-10-29 | 2014-05-09 | 아주대학교산학협력단 | 리포좀 캡슐화를 이용한 산화안정성이 우수한 아스타잔틴의 제조방법 |
CN104997647A (zh) * | 2015-07-09 | 2015-10-28 | 西安艾尔菲生物科技有限公司 | 一种含有虾青素的防晒喷雾剂及其制备方法 |
CN105769820A (zh) * | 2016-04-08 | 2016-07-20 | 华南理工大学 | 一种超临界溶析技术制备虾青素缓释微球制剂的方法 |
CN106726639A (zh) * | 2016-11-28 | 2017-05-31 | 广东工业大学 | 一种peg修饰原花青素脂质体的制备方法 |
CN107271378A (zh) * | 2017-04-13 | 2017-10-20 | 云南民族大学 | 虾青素脂质抗氧化活性的测定方法 |
Non-Patent Citations (4)
Title |
---|
"Progress and Consideration on Fabricating Delivery Systems Containing Astaxanthin", PACKAGING AND FOOD MACHINERY, vol. 35, no. 4, 31 August 2017 (2017-08-31), pages 57 * |
LI, SHUMEI ET AL.: "Preparation of Lycopene Liposomes", CHINESE JOURNAL OF SPECTROSCOPY LABORATORY, vol. 26, no. 2, 31 March 2009 (2009-03-31), pages 282 * |
PENG, CHIUNGHUEI ET AL.: "Improved Membrane Transport of Astaxanthine by Liposomal Encapsulation", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, vol. 75, no. 2, 11 March 2010 (2010-03-11) - 1 June 2010 (2010-06-01), pages 154 - 161, XP027053872, ISSN: 0939-6411 * |
TIAN, YAN-YAN ET AL.: "Preparation of Lycopene Liposomes", FOOD SCIENCE, vol. 28, no. 4, 30 April 2007 (2007-04-30), pages 128 - 132, XP055594336 * |
Also Published As
Publication number | Publication date |
---|---|
CN109691672A (zh) | 2019-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Dai et al. | Curcumin encapsulation in zein-rhamnolipid composite nanoparticles using a pH-driven method | |
Liu et al. | Co-encapsulation of Vitamin C and β-Carotene in liposomes: Storage stability, antioxidant activity, and in vitro gastrointestinal digestion | |
WO2019080193A1 (zh) | 一种包封游离虾青素的脂质体及其制备方法 | |
Tan et al. | Modulation of the carotenoid bioaccessibility through liposomal encapsulation | |
JP5487666B2 (ja) | 内水相を固定化することを特徴とするリポソームの製造方法 | |
JP5494054B2 (ja) | 二段階乳化によるリポソーム製造方法 | |
Wu et al. | Use of sodium alginate coatings to improve bioavailability of liposomes containing DPP-IV inhibitory collagen peptides | |
CN109864244B (zh) | 一种柚皮苷提高β-胡萝卜素脂质体稳定性的方法 | |
WO2024149190A1 (zh) | 一种高稳定性长链不饱和化合物的组合物及其制备方法和用途 | |
Hu et al. | Liposomes encapsulation by pH driven improves the stability, bioaccessibility and bioavailability of urolithin A: A comparative study | |
CN113662187A (zh) | 一种原花青素双重Pickering乳液的制备方法 | |
AU2008339100A1 (en) | Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance | |
Luo et al. | Walnut peptide loaded proliposomes with hydroxyapatite as a carrier: Fabrication, environmental stability, and in vitro digestion attribute | |
JP4669665B2 (ja) | 細胞毒性のないポリカチオン修飾リポソームおよびその製造方法 | |
CN110063945A (zh) | 一种用于急性胰腺炎治疗的胆红素纳米颗粒及其制备方法 | |
CN113521005A (zh) | 一种用于递送白藜芦醇药物的纳米脂质颗粒载体及其制备方法和应用 | |
CN109588711B (zh) | 一种岩藻黄素-牡蛎肽纳米颗粒及其制备方法和应用 | |
CN107625127B (zh) | 南极磷虾油和泛醌的协同抗疲劳组合物、胶囊及制备方法 | |
CN105030673A (zh) | 一种预防药物泄露的高载药量的新型Asulacrine脂质体 | |
CN110507809A (zh) | 一种谷胱甘肽脂质体的制备方法 | |
CN111297805A (zh) | 一种匹莫范色林的脂质体及其制备工艺 | |
CN105497871A (zh) | 一种卡非佐米药物的脂质体冻干组合物及其制备方法 | |
CN110090205A (zh) | 一种绿原酸脂质纳米粒固体分散体的制备方法 | |
CN102626389B (zh) | 一种奥硝唑脂质体注射剂 | |
CN103110931B (zh) | 制备罗咪酯肽脂质体的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17929959 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17929959 Country of ref document: EP Kind code of ref document: A1 |